The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
It has been shown that the interleukin (IL)-23/IL-17 axis is critical in the pathogenesis of psoriasis. ⋯ The superior efficacy of IXE demonstrated at week 12 persisted up to week 24. The safety profiles were consistent with those previously reported for both treatments.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Secukinumab is a fully human antibody that neutralizes interleukin-17A. It has significant efficacy and a favourable safety profile in moderate-to-severe plaque psoriasis and psoriatic arthritis. ⋯ Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.